Literature DB >> 16030090

Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.

Jan J Koornstra1, Fleur E M Rijcken, Corina N A M Oldenhuis, Nynke Zwart, Tineke van der Sluis, Harry Hollema, Elisabeth G E deVries, Josbert J Keller, Johan A Offerhaus, Francis M Giardiello, Jan H Kleibeuker.   

Abstract

Sulindac reduces colorectal cancer risk in genetically susceptible humans and animals. The molecular mechanisms underlying these effects are incompletely understood. Many studies suggest an important role for induction of apoptosis involving the mitochondrial pathway and the death receptor pathway. Alternatively, mechanisms involving the APC-beta-catenin-Wnt pathway have been suggested, possibly mediated by p21. We determined the effects of sulindac on apoptosis and expression of death receptor (DR)-4 and DR5, beta-catenin, and p21 in normal-appearing colorectal epithelium. Biopsies were obtained before and after sulindac treatment during two chemoprevention studies. Patients (n = 18) with hereditary nonpolyposis colorectal cancer (HNPCC) received 150 mg sulindac bd for 4 weeks in a placebo-controlled crossover design. Patients (n = 6) with familial adenomatous polyposis (FAP) received 150 mg sulindac bd for 6 months. Apoptosis was assessed by M30 staining and expression patterns of DR4, DR5, beta-catenin, and p21 were studied immunohistochemically. In HNPCC patients, apoptotic indices were similar following placebo and sulindac. Also in FAP patients, apoptotic indices were not different after sulindac compared with pretreatment values. Expression of DR4 and DR5 was observed in all samples with no consistent differences between placebo/baseline and sulindac. Intensity of membranous beta-catenin staining was lower in HNPCC samples following sulindac compared with placebo (P < 0.001). Similar results were obtained in FAP samples (P < 0.01). p21 expressions before and after sulindac treatment were similar in both patient groups. In conclusion, sulindac inhibits beta-catenin expression in normal colorectal epithelium from HNPCC and FAP patients without affecting apoptotic indices and DR4, DR5, and p21 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030090     DOI: 10.1158/1055-9965.EPI-05-0112

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

Review 1.  Targeting the Wnt signaling pathways in pulmonary arterial hypertension.

Authors:  Vinicio de Jesus Perez; Ke Yuan; Tero-Pekka Alastalo; Edda Spiekerkoetter; Marlene Rabinovitch
Journal:  Drug Discov Today       Date:  2014-06-20       Impact factor: 7.851

2.  Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}.

Authors:  Emily J Greenspan; James P Madigan; Lisa A Boardman; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2011-01

3.  Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations.

Authors:  Hongmei Nan; Teppei Morikawa; Miia Suuriniemi; Yu Imamura; Lillian Werner; Aya Kuchiba; Mai Yamauchi; David J Hunter; Peter Kraft; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino; Matthew L Freedman; Andrew T Chan
Journal:  J Natl Cancer Inst       Date:  2013-12-07       Impact factor: 13.506

4.  A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.

Authors:  Jason D Whitt; Nan Li; Heather N Tinsley; Xi Chen; Wei Zhang; Yonghe Li; Bernard D Gary; Adam B Keeton; Yaguang Xi; Ashraf H Abadi; William E Grizzle; Gary A Piazza
Journal:  Cancer Prev Res (Phila)       Date:  2012-05-03

5.  Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.

Authors:  Ulrike Stein; Franziska Arlt; Janice Smith; Ulrike Sack; Pia Herrmann; Wolfgang Walther; Margit Lemm; Iduna Fichtner; Robert H Shoemaker; Peter M Schlag
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

6.  Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?

Authors:  John M Carethers
Journal:  Curr Colorectal Cancer Rep       Date:  2010-01-13

7.  Sulindac suppresses beta-catenin expression in human cancer cells.

Authors:  Anjia Han; Zibo Song; Chang Tong; Dong Hu; Xiuli Bi; Leonard H Augenlicht; Wancai Yang
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

8.  Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).

Authors:  Haonan Li; Allison L Yang; Yeon Tae Chung; Wanying Zhang; Jie Liao; Guang-Yu Yang
Journal:  Carcinogenesis       Date:  2013-05-20       Impact factor: 4.944

9.  Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice.

Authors:  Balaiya Velmurugan; Rana P Singh; Nidhi Kaul; Rajesh Agarwal; Chapla Agarwal
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

Review 10.  Duodenal adenoma surveillance in patients with familial adenomatous polyposis.

Authors:  Fábio Guilherme Campos; Marianny Sulbaran; Adriana Vaz Safatle-Ribeiro; Carlos Augusto Real Martinez
Journal:  World J Gastrointest Endosc       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.